FBR Medical

About Us


We intend to lead the heart recovery field, a market worth $12 billion.


Heart disease is the leading cause of death worldwide, responsible for almost one-third of all deaths. To treat heart disease, each year U.S. physicians perform more than two million cardiovascular procedures. And another 400,000 U.S. patients are so sick they cannot even undergo such a life-saving procedure without substantial cardiac support.


Recently, new cardiac support devices have emerged to treat heart disease patients and allow them to recover. Most patients recover within hours, and the device is removed.


Our only meaningful competitor was acquired in December 2022 for $17 billion.


Our data indicate our low-cost, life-saving devices may help heart disease patients recover more effectively and with fewer complications than our competitor’s. Specifically, we believe our proprietary devices provide:

  • Ease of use
  • More blood flow
  • Gentler blood flow (less red blood cell destruction, or hemolysis)
  • More substantial heart recovery
  • Better patient outcomes
  • Lower cost


FBR has been granted 13 patents and 14 additional patents are pending


FBR’s founder has invested $5 million developing our products.


The previous cardiovascular company our founder started was acquired for $1.1 billion. In addition, our founder was the first Manager of Business Development for Gilead Sciences (NASDAQ: GILD), a pioneering biotechnology company.

Our COO has commercialized more than a dozen unique medical product platforms. He most recently served as a senior operating officer at Clearpoint Neuro (NASDAQ: CLPT) and Edwards Lifesciences (NASDAQ: EW). 


We project that in 2026 we will generate $2.8 M of revenue and then grow rapidly. By 2030, we project $270 M of revenue, $67 M of operating income, and $47 M of net income.

Play Video

Selected Information

(The complete slide deck appears in the Investors section.)



FBR Medical is pleased to announce the initiation of our seed financing round, our first funding round after our founder’s $5M investment. Investors should select the Investors link for more information.



Chief Executive Officer

Robert B. Fine, M.D., M.B.A.

Our founder and CEO incorporated FBR in 2015 and assigned his ownership of the technology to the Company. Since then, he has personally invested more than $4 million in the Company ($5 million including his investments before incorporation.).

Prior to founding FBR, he founded Kriton Medical – which later became HeartWare. During his time as CEO, the company developed a complex cardiovascular device that generated all of the company’s revenue. In 2016, HeartWare was acquired for $1.1 billion.

Our founder was the original Business Development Manager for then start-up Gilead Sciences (NASDAQ: GILD). He was also a Nomura Research analyst and a Merrill Lynch investment banker.

Our founder was awarded an M.B.A. degree by Harvard and M.D. and A.B. degrees by Columbia University. He completed post-doctoral research at U.C.S.F. and a medical/surgical internship at California Pacific.

Chief Operating Officer

Peter Piferi, M.B.A.

Our COO most recently served as a senior operating officer at Clearpoint Neuro (NASDAQ: CLPT) and Edwards Lifesciences (NASDAQ: EW). Mr. Piferi has commercialized more than a dozen unique medical product platforms. He has developed numerous technically challenging implantable and disposable medical devices, including a permanent implantable blood pump and complex cardiovascular catheters. Mr. Piferi has been issued 47 patents. He has an M.B.A. from Rensselaer Polytechnic Institute.

Consulting Physician/Medical Officer

Naresh Solankhi, M.D.

Dr. Solankhi is the Director of the Catheter Laboratory at Jewish Hospital in Louisville, KY as well as an Assistant Clinical Professor of Medicine at the University of Louisville, KY. He has performed thousands of interventional cardiology procedures and has been the local principal investigator for 35 multi-center clinical trials.

Dr. Solankhi completed a residency in internal medicine at The Cleveland Clinic Foundation and fellowships in cardiovascular medicine at Mt. Sinai School of Medicine and interventional cardiology at St. Paul’s Hospital, University of British Columbia.

Join our Team

FBR Medical Intends to lead the heart recovery market.

Joining FBR Medical presents an exciting opportunity to become part of our dynamic and innovative team developing life-saving cardiovascular devices. We believe in fostering a collaborative and challenging environment where you can thrive and reach your potential. You will also experience the personal gratification knowing that your work will contribute to saving lives.  

Whether you are an engineer or technician, a clinical or regulatory professional, or a financial, accounting, or administrative executive, we look forward to having you join our team.

Open Opportunities

Click on arrows to see more opportunities.


Please provide the information requested below and we will respond as soon as possible.

Investor front page

Are you an accredited Investor?

How did you hear about us?

heart disease

Heart Disease

Heart disease is the leading cause of death worldwide, responsible for almost one-third of all deaths.

Symptoms include chest pain (angina) and shortness of breath.

The American Heart Association (AHA) estimates that 18.2 million U.S. patients are living with heart disease. In the U.S. each year, approximately one million patients are discharged from U.S. hospitals with heart disease, 805,000 suffer a heart attack, and 695,000 people die. This considerable human toll will continue as the population ages.

Heart Disease Treatment

U.S. physicians in 2018 performed approximately 2.1 million cardiovascular procedures, most often to improve coronary artery blood flow. That year, cardiologists performed 684,000 cardiac angioplasties and stent implantations, and cardiac surgeons performed 202,000 coronary artery bypass graft surgeries. We believe many of these patients would have benefited from cardiac support during their procedures, and that an additional 400,000 patients were too severely ill to even undergo such a procedure.

Contact us

contact frontpage


Accepted file types: doc, pdf, Max. file size: 100 MB.